Merck
Merck Q2 Revenues Grow 22 Percent
The company's pharmaceutical revenues were led by robust sales of Keytruda, which racked up $4.18 billion during the quarter.
Merck's Keytruda Nets Two FDA Full Approvals in Triple-Negative Breast Cancer
The PD-1 inhibitor is now approved as neoadjuvant and adjuvant therapy for high-risk early-stage TNBC, as well as for later-stage, PD-L1-high TNBC patients with chemo.
FDA Grants Full Approval to Merck, Eisai's Keytruda, Lenvima Combo in Endometrial Cancer
Based on results from the Phase III Keynote-775 trial, the agency converted its prior accelerated approval of the regimen to full approval.
Merck Updates Results From Early-Stage TNBC Keytruda Study On Path to Second FDA Approval Bid
Premium
Results from Keynote-522's new interim analysis address several key concerns that prompted the FDA's delayed decision, but other questions remain.
Integrated Tumor, Microbiome Features Influence Immunotherapy Combo Effects in Advanced Melanoma
Gut microbiome features showed ties to treatment response and immune-related adverse events in advanced melanoma patients on a combined checkpoint blockade treatment.
Apr 14, 2021
Mar 25, 2021